1、2024Corporate Responsibility and Public Benefit ReportTable of ContentsFORWARD-LOOKING STATEMENTSThis Corporate Responsibility and Public Benefit Report(this Report)contains forward-looking statements made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934 a
2、nd the Private Securities Litigation Reform Act of 1995(PSLRA).These statements,which are based on our beliefs and expectations as to future outcomes,include,among others,statements and opinions about our future operating results,business plans,objectives,pipeline advancements,benefits of our produc
3、ts,and corporate responsibility or public benefit matters,including information or aspirations regarding sustainability and the environment,employees,philanthropy,supply chain,ethics and governance,cybersecurity and data privacy,and any others that contain the words believe,seek,aim,strive,endeavor,
4、expect,anticipate,intend,estimate,should,could,may,will,plan,or similar expressions,and any other statements contained or incorporated by reference into this Report that are not historical facts.These forward-looking statements are subject to certain risks and uncertainties,such as technological adv
5、ancements,energy prices,government incentives,stakeholder engagement,and those described in our periodic reports filed with the Securities and Exchange Commission(SEC)that could cause actual results to differ materially from anticipated results.These statements may also be based on historical or cur
6、rent goals,targets,aspirations,commitments,or estimates;standards for measuring progress that are still developing;diligence,processes,and internal controls that continue to evolve;certifications,representations,or data provided or reviewed by third parties,including information from acquired entiti
7、es that may be incomplete,subject to ongoing review,pending integration into our reporting processes,or unable to be integrated into our processes;and on assumptions that are subject to change in the future.Consequently,such forward-looking statements are qualified by the cautionary statements,cauti
8、onary language,and risk factors set forth in our periodic reports and documents filed with the SEC,including our most recent Annual Report on Form 10-K,Quarterly Reports on Form 10-Q,and Current Reports on Form 8-K.We claim the protection of the safe harbor contained in the PSLRA for forward-looking
9、 statements.We are providing this information as of the date of publication of this Report and assume no obligation to update or revise the information contained in this Report whether as a result of new information,future events,or any other reason.Inclusion of information in this Report is not an
10、indication that the subject or information is material to United Therapeutics business or operating results as that term is defined for purposes of SEC and other mandatory regulatory reporting.Website references and hyperlinks provided throughout this Report are provided for convenience only,and the
11、 content on the referenced websites is not incorporated by reference into this Report,nor does it constitute a part of this Report.03023014453854This Corporate Responsibility and Public Benefit Report primarily covers our sustainability efforts during 2023.Throughout this Report,we also call out 202
12、4 highlights.Message From Our CEOOur Purpose2023 Year in Review 5Where We Operate 6Our Focus 7Our 2023 PBC Goals and Environmental,Social,and Governance(ESG)Priorities 9Our Patients2023 Progress 15Product Innovation and Clinical Trials 16Organ Research and Development Projects 18Product Quality and
13、Patient Safety 23Patient Engagement 26Our People2023 Progress 31Total Rewards 32Talent Acquisition and Development 33Diversity,Equity,and Inclusion 34Safe and Healthy Workplaces 35Our Planet2023 Progress 39Environmental Stewardship 40Our PracticesGovernance 46Ethics and Compliance 48Grants and Givin
14、g 49Data Privacy and Security 51Enterprise Risk Management and Organizational Resilience 52Reporting Indexes About This Report and Stakeholder Engagement 55GRI Standards 57SASB Topics 72The Task-force on Climate Related Financial Disclosures(TCFD)Framework 761MESSAGE FROM OUR CEO OUR PURPOSEOUR PATI
15、ENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESOur quest to create a brighter future for our patients is taking United Therapeutics(UT)to epic heights.For example,as you will read about in this Report,we achieved two amazing milestones in our organ manufacturing work in 2023.Our UHeartTM from
16、 a 10-gene edited pig was successfully transplanted into a living human in an emergency-use,expanded-access procedure,and surgeons completed a 61-day study of our UThymoKidneyTM xenokidney and thymus in a human pre-clinical model.Most recently in April 2024,a UThymokidney was transplanted into a liv
17、ing donor.This brought the total number of xenotransplantation procedures using organs manufactured by UT to 11 when you include both living human recipients and transplants into brain-dead human organ donors.We also welcomed Miromatrix Medical(Miromatrix)and IVIVA Medical(IVIVA)into the UT family o
18、f companies at the end of 2023.These are two wonderful teams who share our purpose to expand the availability of suitable organs for transplant.Since then,Miromatrix received FDA clearance for the first ever clinical trial of a bioengineered organ,miroliverELAP.These are important achievements towar
19、d our goal to help patients suffering from end-stage organ diseases,and they are possible because of the selfless contributions of organ donors,patients willing to try our experimental organs,and their families.We are humbled and inspired by these noble acts.At the same time,we are grounded in the k
20、nowledge that our pharmaceutical therapies and our ex vivo lung perfusion(EVLP)service are helping patients todayserving more than 14,500 in 2023,including 100 patients benefiting from our EVLP service,which,basically,is an innovation that expands the number of lungs available for transplant.These t
21、wo pursuitsserving unmet needs today while building toward a transformational futureare just another way of saying we are committed to our public benefit purpose.Our purpose compels us to maintain excellent patient safety and quality management programs that help us make sure no patient is left behi
22、nd.It is the impetus for the portfolio of benefits and amenities we offer our employees,and why we aim to operate safely and sustainably in all that we do,because we know that being a destination employer will help us attract and retain the diverse,creative,curious,and mission-driven individuals col
23、lectively trying to accomplish something meaningful every single day.It is also why we are trying to mitigate our climate risks through our sustainable building ambitions and through our efforts in aviation to enable the safe and sustainable delivery of organs to those who need them.We remain confid
24、ent in our future in large part because of our strong governance,ably led by our Executive Leadership Team and our Board of Directors.Im especially gratified to welcome our newest Board member,former Minnesota Commissioner of Health,Jan Malcom,whose career-long dedication to improving healthcare in
25、the public and private sectors will undoubtedly add much value to our Boards oversight efforts.We understand we have more work ahead as we continue to evolve our environmental and social sustainability program and disclosures.Nonetheless,the examples and stories we share offer a glimpse of what we h
26、ave achieved,as well as a roadmap for our potential.We welcome your thoughts about our progress.Dr.Martine Rothblatt Chairperson and CEOMessage From Our CEOMartine Rothblatt,Ph.D.Chairperson and CEO2MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESOur Pur
27、pose5 2023 Year in Review6 Where We Operate 7 Our Focus9 Our 2023 PBC Goals and Environmental,Social,and Governance(ESG)Priorities3MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESOur Business and PurposeUnited Therapeutics Corporation(UT)was founded by p
28、arents trying to save the life of their child who had been diagnosed with a rare and terminal disease we now call pulmonary arterial hypertension(PAH).At the time,there were limited therapies,and the only known cure was thenand still is todaya lung transplant.Saving lives has always been our priorit
29、y.That is why,following the overwhelming approval by our shareholders in 2021,UT became the first-ever publicly traded biotechnology company organized as a public benefit corporation(PBC).This aligns our legal form with our longstanding commitment to serve our patients.We believe it also enhances ou
30、r ability to create superior and sustainable value for all our stakeholders,including our shareholders.To achieve our purpose,we seek to make positive impacts on patients,on our people,whom we call Unitherians,and on the planet.This Report summarizes our ambitions and progress toward these objective
31、s.We are an innovative,commercially successful,dare-to-be-different biotechnology company.Our mission and vision are one.We use our enthusiasm,creativity,and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders.We are bold and unconventional.We ha
32、ve fun,we do good.Individual watercolors by Unitherians visualizing UTs purposeOur public benefit purpose is to provide a brighter future for patients through the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs.4MESSAGE FROM OUR CE
33、O OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXES2023 Year in ReviewServed more than 14,500 patients being treated with our therapiesCompleted acquisitions of Miromatrix and IVIVA,adding additional organ manufacturing technologies to our portfolioProvided organs for Two xen
34、otransplantation procedures in 2023,and one in 2024,bringing the total xenotransplantation procedures using UT manufactured organs to 11Reached record revenue with+20%growth compared to 2022Employed 1,168 employees across 13 locations,including 82 employees who joined us from Miromatrix and IVIVAAch
35、ieved approximately$2.0 million revenue per employee,the highest among our peers*Maintained a low voluntary turnover rate at 5%compared to a 13.5%industry average*Increasing our LEED Certified total square footage to 26%by securing LEED Gold certification for our current Good Manufacturing Practices
36、(cGMP)-compliant warehouse and logistics center*See our 2024 Notice of Annual Meeting of Shareholders and Proxy Statement,page 57.*Industry data from Aon/Radford Turnover study;data published December 2023|U.S.Life Sciences:Biotech/Pharma|Date range for 2023 industry data is June 2022June 2023.This
37、figure includes three xenotransplants into living human patients,and eight transplant into deceased,brain-dead human organ donors with the consent of the donors family.Data as of December 31,2023,unless otherwise noted5MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPO
38、RTING INDEXESWhere We Operate Silver Spring,Md.Research Triangle Park,N.C.Melbourne,Fla.Eden Prairie,Minn.Jacksonville,Fla.Manchester,N.H.Washington,D.C.Bromont,Quebec Medford,Mass.Our co-headquarters are in Silver Spring,Md.,and Research Triangle Park,N.C.,with additional facilities located princip
39、ally in North America.Selected locations include:Recent Awards and Recognition HighlightsNewsweeks Americas Most Responsible Companies 2024 third consecutive yearFortune Great Place to Work 2024 seventh consecutive yearFortune Best Workplaces in BioPharma 2023 (Small and Medium)Fortune Best Medium W
40、orkplaces 2023Fortune Best Workplaces for Millennials 2023 (Small and Medium)6MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESOur FocusWe seek to develop life-extending therapies and technologies for patients in two core areas:lung disease and organ manu
41、facturing.The defining characteristics of our patients are two-fold:their conditions are extremely rare and they are life-threatening.While we continue to develop and commercialize therapies for these conditions,we view organ manufacturing as a complementary solution for a broad array of diseases,ma
42、ny of which,such as pulmonary hypertension(PH),have proven incurable to date through more traditional pharmaceutical and biologic therapies.PAH 45,000Rare DiseaseU.S.Patient PopulationsNeuroblastoma 800PH-ILD 30,000 Tyvaso and Tyvaso DPI are inhaled prostacyclin analogues approved for the treatment
43、of PAH and PH associated with interstitial lung disease(PH-ILD)(WHO Group 3)to improve the ability to exercise.They are the:First products approved to treat PH-ILD,and The most prescribed U.S.prostacyclin therapiesImportant Safety Information(ISI):https:/ is approved to diminish symptoms associated
44、with exercise in patients with PAH.It is the most prescribed parenteral prostacyclin in the U.S.,and Has been recommended in treatment guidelines since 2003ISI:https:/ is a Phosphodiesterase 5(PDE5i)*inhibitor approved for treatment of PAH to improve exercise ability.ISI:https:/ is an orally-adminis
45、tered prostacyclin analogue for the treatment of PAH patients to delay disease progression and improve exercise capacity.ISI:https:/ inhibitors are a type of drug that can affect blood flow and how cells communicate in the body.*It is a monoclonal antibody,which means it is an immune system protein
46、made in a lab by scientists and is specialized to target specific cells.We also manufacture and commercialize a therapy to treat neuroblastoma,a rare form of pediatric cancer affecting approximately 800 children in the U.S.Unituxin is the first antibody therapy approved to treat this type of cancer
47、and the most prescribed antibody therapy for high-risk neuroblastoma in the U.S.*ISI:https:/ Products for Pulmonary Hypertension(PH)7MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXES17 Number of people that die each day waiting for transplant9%Increase in
48、 organ transplants performed(2023/2022)100,000 Number of people on the U.S.national transplant waiting listOrgan Manufacturing U.S.Organ Transplant Data*According to the U.S.Health Resources and Services Administration(HRSA),one new person joins the organ transplant list about every eight minutes.So
49、urce:“Organ Donation Statistics.”HRSA organdonor.gov.https:/www.organdonor.gov/learn/organ-donation-statistics.Accessed June 2024.At UT,we strive to help address the gap between the need and the availability of suitable organs for transplant.Through our ex vivo lung perfusion(EVLP)service,we are inc
50、reasing the number of organs available for transplant today We are innovating solutions that we believe will soon help save even more peoples lives through our xenotransplantation efforts at our Revivicor subsidiary and our regenerative medicine work We are progressing the science of manufactured or
51、gans through our bio-artificial liver and kidney organ research under way at our Miromatrix and IVIVA subsidiaries We are building toward a longer-term vision to be able to supply 3D-printed organs for all who need themProgress across these efforts help us learn more about the functionality and biol
52、ogy of the four key organs of focuslung,heart,kidney,and liver.Simultaneously,we are engaging the community of regulators,healthcare professionals(HCPs),and academic programs where future surgeons will be trained,at the same time we seek to support the organ transplant logistics infrastructure.46,00
53、0 Organ transplants performed in 20238MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESOur 2023 PBC Goals and Environmental,Social,and Governance(ESG)PrioritiesOur PBC legal form requires that we provide our shareholders and other stakeholders with a bien
54、nial update on how we are advancing our public benefit purpose and the interests of our other stakeholders.We decided to report our PBC progress annually.We align our PBC goals with our three core stakeholder groupsOur Patients,Our People,and Our Planet.Cognizant of the fact that our work affects an
55、d is affected by the world,and that there is significant overlap between our PBC goals,objectives,and metrics and ESG topics,we use our PBC framework as the structure for our ESG priorities and reporting.We also strive to align our efforts and impacts with the internationally recognized blueprint fo
56、r peace and prosperity for people and the planet identified in the 17 United Nations Sustainable Development Goals(UN SDGs).This report summarizes our ambitions and progress.We have deliberately scaled back the narrative this year to make this Report easier to navigate and digest.We invite readers i
57、nterested in or needing more details to explore the wealth of information available in the Reports and Other Resources section on our Corporate Responsibility website and by navigating to the links provided throughout this document.The Biowall and plaza at UTs co-headquarters in Silver Spring,Md.9ME
58、SSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESOUR 2023 PBC AND ESG KEY PERFORMANCE INDICATOR SUMMARYOur PBC GoalsKey Performance Indicators2023 ProgressUN SDG AlignmentOUR PATIENTSAddress Unserved NeedsWe aim to conduct the most insightful clinical trial
59、s with our medicines in areas of high unmet medical need.Number of patients being treated with our therapies Over 14,500 patients being treated with our therapies,including 100 patients benefiting from our centralized ex vivo lung perfusion(EVLP)service$408 million invested in R&D in 2023 10 ongoing
60、 clinical trials engaging more than 1,700 volunteers,including one trial studying a potential product extension to treat progressive pulmonary fibrosis(PPF)Two successful xenotransplantations in 2023one into a living human and one into a human pre-clinical model;with one more in 2024,the total numbe
61、r of xenotransplantation procedures using UT organs was 11 as of July 31,2024 R&D milestones,including clinical trial results,regulatory approvals,and progress on R&D projectsNo Patient Left BehindWe aim to ensure that all patients who are appropriate for use of our medicines can do so,regardless of
62、 their financial situation.Patient support programs Supported over 32,000 patients on their treatment journey since 2010 Provide generous patient access programs Zero Good Manufacturing Practice(GMP)related issues at UT-owned facilities that would prevent use or approval of our products Maintained t
63、wo-year or more inventory for most of our therapiesReliable supply chainmet or exceeded targetsmade progress and continuing to advancedelayed or deferred to future dateKey:10MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXES*Industry data from Aon/Radford
64、Turnover study;data published December 2023|U.S.Life Sciences:Biotech/Pharma|Date range for 2023 industry data is June 2022 June 2023OUR 2023 PBC AND ESG KEY PERFORMANCE INDICATOR SUMMARYOur PBC GoalsKey Performance Indicators2023 ProgressUN SDG AlignmentOUR PEOPLEBe a Destination EmployerWe aim for
65、 United Therapeutics to be a destination employer by creating a mission-centric,diverse,and inclusive environment where Unitherians are inspired by the challenging work ahead of us and the opportunity to grow and advance their careersVoluntary turnover Voluntary turnover of 5%,compared to a 13.5%ind
66、ustry average*Overall workforce diversity:52%identify as women,35%identify as racially/ethnically diverse Board Diversity:42%identify as women,25%as racially/ethnically diverse More than 90%of employees who responded to the Great Places to Work survey from 2018 through 2024 consider UT a Great Place
67、 to Work Diversity,equity,and inclusion(DEI)initiatives and programsEmployeeengagement as measured by surveys OUR PLANETOperate SustainablyWe aim to mitigate our environmental impact and operate in a sustainable fashionNew buildings net zero when feasible Secured LEED Gold Certification at our Phase
68、 Five,cold storage cGMP warehouse in Research Triangle Park,N.C.Maintained almost 7-MW onsite solar capacity Made progress toward assurable Scope 1 and 2 GHG emissions Environmental data trends(e.g.,energy,water,waste)Progress toward assurable Scope 1 and 2 greenhouse gas(GHG)emissions inventoriesme
69、t or exceeded targetsmade progress and continuing to advancedelayed or deferred to future dateKey:11MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXES2024 PBC Metrics and ESG Prioritization ApproachThe Nominating and Governance Committee of our Board annua
70、lly reviews and approves any adjustments to our PBC objectives and key performance indicators,based on recommendations from our cross-functional,management-level ESG Cabinet for implementation in the following fiscal year.We expect to continue to update our objectives and key performance indicators
71、as we work toward our purpose with the partners in our supply chain,our collaborators in scientific exploration,and the communities in which we work and live.In 2024,we worked with a third party to undertake a new ESG prioritization assessment and refresh our understanding of the priority ESG topics
72、 that could affect our business,our long-term ability to create stakeholder value,and our ability to serve our PBC purpose.We considered input from internal stakeholderssenior leaders and employeesand integrated feedback from a broad range of external stakeholders,including investors and customers.W
73、e also considered industry peers and industry-leading practices,leading rating organizations,and third-party reporting frameworks,including the Sustainability Accounting Standards Board(SASB)and the Task Force on Climate-related Financial Disclosures(TCFD).Our process is outlined below:1.Identifying
74、 Topics:We used our previous priority topics as a starting point and identified additional ESG topics across United Therapeutics value chain for consideration through a detailed review of internal and external sources.2.Engaging with Stakeholders:We refined our list of identified ESG topics through
75、direct engagement with senior leaders,which was further informed by feedback and findings from external stakeholders,such as investor engagement and questionnaires from customers.3.Scoring and Evaluating:We scored each data source and stakeholder group to determine the priority topics for us and the
76、ir importance to our business.Results were validated by our executive leadership team.We mapped the resulting ESG priority list to our PBC goals and metrics,aligned with our core stakeholders.The illustration on the next page depicts how these ESG topics align with and are supportive of our PBC purp
77、ose.Topics are presented in alphabetical order.The results of our 2024 assessment reaffirm our corporate responsibility and sustainability journey and inform some of the narrative in this Report.We will strive to enhance our disclosures in alignment with these ESG priorities in our future disclosure
78、s.LEARN MOREFor more details,see About This Report and Stakeholder Engagement on page 55 of this Report.For details about our Board oversight of our ESG and PBC objectives,see ESG and PBC Governance on page 46.12MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING I
79、NDEXESOur PBC and ESG PrioritiesThe following chart illustrates our alignment of our PBC framework and top ESG priorities.To provide a brighter future for patients through the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organsOUR PURP
80、OSEOUR KEY STAKEHOLDERSOUR PBC GOALSOUR PBC KEY PERFORMANCE INDICATORSPRIORITY ESG TOPICSOUR PRACTICESOur PatientsAddress unserved needs Number of patients on therapy R&D milestones,including clinical trial progress,regulatory approvals,and progress on organ R&D projects Clinical Trial Practices Hea
81、lthcare Provider Awareness and Education Pipeline Innovation Product Affordability and Accessibility Product Quality and Patient Safety Responsible Marketing and Advertising Supplier Product Quality and Compliance Key Enablers Governance,Data Privacy and Security,Compliance Culture and Ethics,and En
82、terprise Risk and Organizational ResiliencePRIORITY TOPICS:Ethics and Compliance,Risk,and Crisis ManagementTalent Attraction,Engagement,and Development Carbon GHG EmissionsResource Use Management (energy,water,waste)Patient Assistance Program(PAP)and Specialty Pharmacy(SP)support Reliable Supply:Inv
83、entory and Supply Chain Reliability Voluntary turnover Diversity metrics and DEI initiatives Employee engagement as measured by third party(i.e.,Best Place to Work)and internal survey New buildings net zero when feasible Environmental data trends(e.g.,energy,water,waste)Progress toward assurable Sco
84、pe 1 and 2 greenhouse gas(GHG)emissions inventories NEW:Develop initial climate risk and opportunity assessment by 2025 NEW:Integrate environmental principles to the extent feasible into new product packagingNo patient left behindOur PlanetOur PeopleBe a destination employerOperate sustainability13M
85、ESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESOur Patients15 2023 Progress16 Product Innovation and Clinical Trials18 Organ Research and Development Projects23 Product Quality and Patient Safety26 Patient EngagementMESSAGE FROM OUR CEO OUR PURPOSEOUR PA
86、TIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXES142023 ProgressCreating a brighter future for our patients is our top ambition,which is why we align two of our four PBC goalsAddress Unserved Needs and No Patient Left Behindwith our patients.It is also why we align several priority ESG topics
87、 with this important stakeholder group.Our Key Performance Indicators Number of patients being treated with our therapies R&D milestones,including clinical trial progress,regulatory approvals,and progress on organ R&D projects PAP and SP support Reliable Supply:Inventory and Supply Chain Reliability
88、Progress HighlightsServed just over 14,500 patients being treated with our therapies,including 100+patients benefiting from our centralized EVLP service in 2023 alone,bringing the total EVLP-assisted transplantation patients served since launch to 400+UN SDGs AlignmentSupported successful xenotransp
89、lantation of a porcine heart(UHeart)into a living human,and 61-day study of a xenokidney and porcine thymus(UThymoKidney)into a human pre-clinical model*Invested$408 million in research and developmentInitiated the phase 3 TETON PPF study of nebulized Tyvaso in patients with PPFSupported 10 ongoing
90、clinical trials engaging more than 1,700 volunteersSupported over 32,000 patients on their treatment journey since 2010Maintained relationships with 600+pre-qualified raw material vendors and service providersProvided generous patient access programs,including a$0 co-pay card for PH products for eli
91、gible patients,and a patient assistance program for our productsHad zero GMP related issues at UT-owned facilities that would prevent use or approval of our productsMaintained a two-year or more inventory of nebulized Tyvaso,Remodulin,and Orenitram*Our xenotransplantation products are investigationa
92、l-stage products.United Therapeutics is preparing for clinical trials of our xenokidney,xenothymokidney,and xenoheart products following completion of ongoing preclinical studies required by the U.S.Food and Drug Administration(FDA).All xenotransplants into living humans using UT organs were authori
93、zed by the FDA under the expanded access pathway,sometimes called“compassionate use”.15MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESProduct Innovation and Clinical TrialsOur product portfolio helps to address the critical and unmet needs of patients w
94、ith rare diseases and end-stage organ disease.PH therapies:With a focus on rare lung diseases,most of our therapies are concentrated in PAH and PH-ILD.We are actively working to improve our delivery systems to administer our therapies to enhance convenience,safety,and patient outcomes.We are also st
95、udying additional indications for our leading product Tyvaso,efforts that led to FDA approval of nebulized Tyvaso to treat PH-ILD in addition to PAH in 2021,and approval in 2022 of Tyvaso DPI to treat both PAH and PH-ILD.LEARN MOREOur Therapeutic Areas and Product OfferingsOur PipelineAbout Pulmonar
96、y HypertensionPH is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart.PAH is one form of PH that affects the blood vessels in the lungs and is characterized by increased pressure in the pulmonary arteries,which are the blood vessels leading from the
97、 heart to the lungs.The elevated pressure in the pulmonary arteries strains the right side of the heart as it pumps blood to the lungs.This eventually leads to right heart failure and,sadly,death.PH-ILD is a rare and serious progressive disease that results from a combination of high blood pressure
98、in the lungs(due to narrowing of the blood vessels that causes the heart to work harder)plus any one or more of a group of progressive lung disorders that cause lung tissue to stiffen,making it harder to breathe.The only known cure for PAH and PH-ILD is a lung transplant.Oncology therapy:Neuroblasto
99、ma is a cancerous tumor that begins in nerve tissue of infants and very young children.Unituxin was the first antibody therapy FDA-approved to treat children with high-risk neuroblastoma.Patients are at the center of everything that we do at United Therapeutics.UT was founded because of a patient wi
100、th PAH.Everyone who works here recognizes that this is at the core of what we do and are really proud of that.”Gil Golden MD,Ph.D.Chief Medical Officer 16MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESClinical Trials Clinical trials assess the efficacy
101、and safety of our medicines,medical devices,and the transplantable organs we produce.Patient-volunteers make clinical trials possible.In 2023,we had close to 1,700 volunteers participating in 10 clinical trials.During the past year,regulatory inspections of our clinical trials resulted in zero requi
102、red voluntary or official actions or monetary fines.Clinical trials in the U.S.must be registered with www.clinicaltrials.gov.We are committed to conducting our trials in compliance with laws,regulations,and guidelines for the protection of human subjects,including guidelines issued by the Internati
103、onal Council for Harmonization:Good Clinical Practice(ICH-GCP).We conduct compliance audits related to our clinical trials and are subject to periodic external audits by health authority inspectors.DEI and Clinical Trials:DEI in clinical trials is an increasingly important ESG issue.Our teams unders
104、tand that non-medical factors like education and awareness can influence health outcomes,and that the more aware and educated health care professionals(HCP)and patients are about these diseases,the more effectively we can reach underserved populations.That is why we believe our patient education and
105、 empowerment,HCP support,and training for nurses and pharmacists in SPs are critical to providing effective management of the diseases we cover.Just as important is HCP knowledge and awareness of clinical trial opportunities for their patients.We continue to work with HCPs to increase awareness of o
106、ur clinical trials.LEARN MORE For more details,see Our Approach to Patient Engagement on page 26 in this Report.Our Clinical TrialsOur Global Patient Safety and Vigilance Overview,which covers clinical trial safety audit and oversight17MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANET
107、OUR PRACTICESREPORTING INDEXESOrgan Research and Development ProjectsThe only known cure for the diseases our key therapies treat is an organ transplant,which is why our companion purpose is to reduce the progression of,and ultimately cure end-stage organ disease through our organ manufacturing prog
108、rams.Our strong growth helps us reinvest in our important organ manufacturing development.Using a“multiple shots on goal”approacha concept borrowed from sportswe are pursuing a wide array of technologies.Through their progress,each can enhance the potential for success of the others.TimeUnited Thera
109、peutics Organ Manufacturing JourneyEx vivo LungPerfusionXenotransplantationRegenerativeMedicine andBio-artificial Organs3D-AutologousPrinted OrgansTodayNear TermNext Leap ForwardThe FutureNumber of Transplantable OrgansThis chart is a qualitative depiction and should not be interpreted as reflecting
110、 real-world data.MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXES18EVLP Increasing the Number of Organs Available for Transplant TodaySince 2014,we have been developing technologies and services with the aim of increasing the number of human donor lungs
111、for transplant.In addition to conducting EVLP,our Lung Bioengineering(LBE)centralized service model is designed to provide 24/7 year-round procurement,transport,and logistics support to help practitioners navigate the complicated terrain of transplantation.Highlights More than 400 patients have rece
112、ived lung transplants to date following use of our centralized EVLP model,including more than 100 in 2023 alone Our expert team of LBE Clinical Specialists use the XVIVO Perfusion System(XPS)with STEEN Solutionthe first FDA-approved EVLP device on the market Our OrganVue software is designed to enab
113、le practitioners to remotely engage with LBE Clinical Specialists and make in-depth clinical evaluations of donor lung viability,in real time,at any timeXenotransplantation Expanding the Number of Organs for Transplant in the Near TermXenotransplantation is when non-human cells,tissues,or organs are
114、 used to treat medical conditions in humans.Acquired by United Therapeutics in 2011,Revivicor was the first organization to clone pigs successfully.The company received FDA approval in 2020 for use of GalSafeTM pig as a source for food and human therapeutics.These pigs contain a single gene edit to
115、disrupt the gene responsible for producing the galactose-alpha-1.3-galactose carbohydrate,called“alpha-gal,”on the surface of cells.The presence of alpha-gal causes an immune response in humans and is an important cause of rejection.*Highlights:Starting in 2022,we have been involved in groundbreakin
116、g transplants of our experimental,gene-edited UHeart,UThymoKidney and UKidneys.The data from these procedures have been published in medical journals and provide preclinical evidence that gene edited pig organs could transcend the most proximate immunological barriers to xenotransplantation We opene
117、d the worlds first clinical-scale designated pathogen free(DPF)facility in February 2024 and expect the facility to supply cGMP-compliant xenografts for human clinical trials,with an initial capacity of up to 125 organs per year In April 2024,surgeons at NYU Langone Health successfully transplanted
118、a UThymoKidney and the first ever left ventricular assist device(LVAD)into a living human*Boyle,Patrick.“How pig organs made their way into humans:The slow advance to transplant kidneys and hearts.”Association of American Medical Colleges.23 Feb 2022.URL:https:/www.aamc.org/news/how-pig-organs-made-
119、their-way-humans-slow-advance-transplant-kidneys-and-hearts.Accessed June 2024.UT EVLP Specialists in Jacksonville,Fla.work on a donor lungOriginal art commissioned for the opening of the DPF19MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESLEARN MORE Ou
120、r Organ Manufacturing OverviewOur Lung Bioengineering ServicesOur Revivicor subsidiaryOur Miromatrix subsidiaryOur IVIVA subsidiary3D-Autologous Printed(3DAP)Organ The FutureOur bodies immune systems have evolved to protect us from substances or objects they recognize as“foreign”and reject them.Exce
121、pt for rare transplants between identical twins,organ transplantation(whether allotransplantation or xenotransplantation)has historically required recipients to take immunosuppressive drugs to prevent rejection of the transplanted organ by the recipients body.Our 3DAP Lung is a development-stage pro
122、duct made of a high-resolution lung scaffold that is 3D-printed with bioinks and then cellularized with a patients own cells to create tolerable,transplantable,personalized organs that should not require immunosuppression to prevent rejection.Highlights:Our 3D-printed lung scaffold is the most detai
123、led 3D-printed object in the world today,composed of about 44 trillion voxels(voxels are 3D pixels)A single 3D-printed lung lobe scaffold includes 200 million alveoli,about 67%of those in an average human lung today,and approximately 4,000 kilometers of pulmonary capillaries(about 2,500 miles,or rou
124、ghly the distance between New York City,N.Y.and Las Vegas,Nev.)3D-printed lung scaffoldRegenerative Medicine and Bio-artificial Organs The Next Leap ForwardThrough our regenerative medicine and bio-artificial bioengineering programs,we seek to engineer organs using porcine organ scaffolds combined w
125、ith human donor(allogeneic)cells to produce a human-like organ.Highlights:In 2024,UT company Miromatrix received FDA clearance for the first-ever clinical trial of a bioengineered organmiroliverELAP,an investigational-stage external liver assist product(ELAP)designed to provide liver support in crit
126、ical care settings In 2023,our Regenerative Medicine Laboratory in Research Triangle Park,N.C.produced 450 decellularized lung scaffolds,220 recellularized lungs,and 1.7 trillion human cells for use in recellularizationMiromatrix liver bioreactor20MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOP
127、LEOUR PLANETOUR PRACTICESREPORTING INDEXESSustainable Aviation for Organ Delivery The safe and efficient transportation of organs is not easy.Flight or ground transportation delays can close a precious window of viability in which a recipient waits for a life-saving organ to arrive.Since its incepti
128、on in 2017,our wholly-owned subsidiary,Unither Bioelectronics,has reached several groundbreaking milestones.For example,the team completed the worlds first successful drone delivery of donor lungs between two hospitals in Toronto in September 2021.In 2022,the team performed the first all-electric cr
129、oss-country helicopter flight.Most recently,in 2024,the team announced that it is doing research into the development of hydrogen fuel-cell powered aircraft.In recognition of its groundbreaking and deeply humanitarian efforts,Mikal Cardinal,VP of Program Management,Organ Delivery Systems,and team ac
130、cepted the inaugural Aro Montral Enterprise Innovation Award at the 2024 International Aerospace Innovation Forum.Other InnovationsThe Unither Bioelectronics team accepts the 2024 Aro Montral Enterprise Award21MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING IND
131、EXESThe BIG IdeaAfter the 2020 BIG Idea success,we relaunched The BIG Idea Challenge in 2023.Unitherians were invited to share their ideas for new business models,products,services,and improvements in the patient or HCP experience.Applicants in 2023 were eligible for up to$100,000 in pilot funding t
132、o bring the winning idea to life.As in 2021,finalists were invited to a“Shark Tank”-style pitch,broadcast to all Unitherians,before a panel of five judges:two members of our Board of Directors and three senior executives.2023 WINNING BIG IDEA:THE EASYDILExcited by the opportunity to decrease the bur
133、den of PAH and a therapeutic delivery system on patients lives,the winning team pitched a conceptthe EasyDilthat seeks to simplify and streamline the Remodulin dilution process.Remodulin patients must complete complicated drug dilution procedures to prepare their prescribed dose for intravenous inje
134、ction.As of mid-2024,the team created three prototypes of the solution to improve the patient user experience and is working with an external firm to conduct user testing with patients and caregivers to identify the option they most prefer.EasyDil team members are a cross functional team who came to
135、gether to solve a patient challenge.Team members include Assaf Shaked,Sr.Director,Medical Device Development,Timothy Atolagbe,Senior Process Development Specialist,Purification,Tom Baran,Associate VP,Medical Device Development,Adam Elias,Lead Product Development Engineer,Medical Device Development,S
136、am Mancuso,Sr.VP of Global Quality,Lauren Morgan-Schatz,Field Director,Clinical Product Training,and Ian Voos,Product Development Engineer,Medical Device Development.The Big Idea program democratizes innovation by engaging all Unitherians in the process,and the results are solutions that aim to impr
137、ove the quality of life of patients.Since the inception of the program,Unitherians have submitted more than 140 novel ideas.Whats more,some team members whose submissions were not selected by our panel were so inspired by the effort that they secured approval from supervisors to move them forward an
138、yway,further fostering UTs culture of innovation.”Shola Oyewole VP,Digital Innovation 22MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESProduct Quality and Patient SafetyProtecting and improving patient health and quality of life is our core objective an
139、d reinforced through our public benefit purpose.Our first two compliance principlesWe Do the Right Thing,and We Are Passionate for Patientslink to this core objective,and inspire us to strive toward the following:We get the right products,to the right patients,for the right reasons We manufacture wi
140、th the highest quality standards We promptly communicate information about adverse event occurrences and complaints related to our products We proactively observe,assess,and implement required measures to mitigate their effects on patients and improve their overall quality of lifeAll Unitherians are
141、 responsible for safeguarding patients health,product quality,and helping achieve compliance with UTs policies and standards.Global Patient Safety and VigilanceWe monitor the use of our therapies throughout the product lifecycle globally,starting from development programs through the post-approval p
142、hase to identify potential side effects,product issues,and institute risk minimization measures to maintain a positive benefit-risk balance.We strive to adhere to best practices in accordance with the latest editions of relevant regulatory and international standards,which include the following:Good
143、 Pharmacovigilance Practices and Pharmacoepeidemiolgic Assessment,FDA Good Pharmacovigilance Practices,European Medicines Agency Safety Guidelines,International Conference on Harmonization Patient Safety,World Health OrganizationWe provide mandatory training to our employees and third-party collabor
144、ators to help provide for the proper identification,rapid collection,and reporting of adverse events and product complaints with use of our therapies.Patient safety is a mission;the only way to achieve it is by continuous vigilance.”Ravi Patel RPh,PharmD,MBA Sr.VP,Global Patient SafetyZero product r
145、ecalls in 202323MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESOur Patient Safety,Governance,and OperationsTo achieve rapid evaluation of signals*and decision making related to risk minimization measures,we have established a robust safety governance st
146、ructure that operates under a comprehensive and strict set of standards.Patient safety and safety risk management are at the core of our Patient Safety practice.Our Patient Safety team regularly monitors reported adverse events and product complaints to identify potential risks that could trigger ri
147、sk minimization measures.We direct our patients to report suspected adverse impacts by contacting United Therapeutics at 1-866-458-6479 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch,and information provided to us is treated in accordance with our Privacy Statement on our website.*A signal is
148、defined as“information that arises from one or multiple sources(including observations and experiments),which suggests a new potentially causal association,or a new aspect of a known association,between an intervention and an event or set of related events,either adverse or beneficial,which would co
149、mmand regulatory,societal or clinical attention,and is judged to be of sufficient likelihood to justify verificatory and,when necessary,remedial actions.”This definition was adopted by the Council for International Organizations of Medical Science in 2010(https:/cioms.ch/publications/product/glossar
150、y-of-ich-terms-and-definitions/).PRODUCT SAFETY REVIEW COMMITTEE(PSRC)Executive EndorsementChaired by our head of Global Patient Safety,and comprised of leaders from Patient Safety,Quality,Compliance,R&D,Medical,and Operations,this committee oversees our safety risk management activities.The Committ
151、ee meets at least quarterly to endorse recommended actions proposed by the Product Safety Management Team to protect patient safety based on comprehensive reviews of data across locations,populations,drugs,biologics,devices,and combination products.PRODUCT SAFETY MANAGEMENT TEAMSignal Validation and
152、 Risk MinimizationComposed of medical,scientific,and quality experts,this team is responsible for evaluating and confirming safety trends or signals and recommending risk mitigation strategies to the PSRC.The team is accountable directly to our head of Global Patient Safety.GLOBAL PATIENT SAFETY AND
153、 VIGILANCESignal Review and EvaluationOur head of Global Patient Safety provides strategic and operational oversight of the end-to-end Patient Safety Program and provides vigilance support to Clinical Operations,Quality,Manufacturing,Medical Affairs,and Product Development teams.LEARN MORE Our Globa
154、l Patient Safety and Vigilance OverviewOur Global Patient Safety and Vigilance webpage24MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESQuality OperationsWe are committed to leading industry practice through our GxP Quality and Compliance program,support
155、ed by a digital Quality Management System.GxP refers to Good Manufacturing Practices(GMP*),as well as Good Clinical Practices,Good Distribution Practices,Good Laboratory Practices,Good Tissue Practices,and Good Vigilance Practices.Our Global Quality Policy and supporting policies and standard operat
156、ing procedures together establish guidelines designed to assure quality,safety,and efficacy in the marketing and distribution of products.*We adhere to FDA GMP standards and are committed to improvement,striving to apply cGMP across our manufacturing operations.Our Quality Policy covers all full-and
157、 part-time employees and extends to relevant contractors,sub-contractors,and temporary labor.Suppliers that could affect the quality and safety of our products are required to comply with GMP regulations,enforced by the FDA,and have their own Quality Policy,which is reviewed during qualification and
158、 subsequent monitoring.Quality Policy StatementUnitherians United Therapeutics employees are committed to providing safe and effective therapeutic products to enrich the quality of life for our patients.We will continually achieve our mission through improving scientific innovation,enhancing the qua
159、lity management system,complying with regulatory requirements,and meeting the expectations of our customers.GP-001 Revision 02Sam Mancuso Quality Management System Representative Senior Vice President,Global QualityDr.Martine Rothblatt Chairperson and Chief Executive OfficerReliable Supply A corners
160、tone of our PBC objectives is to have sufficient inventory to maintain uninterrupted supply to our patients.As noted in our 2023 Corporate Responsibility and Public Benefit Report,we aim to maintain,at a minimum,a two-year inventory of nebulized Tyvaso,Remodulin,and Orenitram,and work with third-par
161、ty manufacturers to supplement our supply.We continue to build the operations needed to deliver on our promise of having adequate inventory for our patients.See information about our Phase Five warehouse in our Sustainable Facilities Overview on our Corporate Responsibility website.LEARN MOREOur Qua
162、lity Management Overview100%completion of required GMP training for all new hires and for employees who directly perform GMP activitiesUnitherians collaborating on quality assurance25MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESPatient EngagementFor o
163、ver 27 years,we have been serving a patient population with underserved diseases aiming to provide them with breakthrough medicine and ensure all eligible patients have access to medicine regardless of their financial condition.The diseases that affect our patients are rare,which means they are ofte
164、n undertreated.In addition to therapeutic development,we take a multi-faceted approach to helping patients by:Engaging HCPs to educate them about these diseases and treatments to help enable them to diagnose earlier and treat in accordance with the latest standards of care Sharing educational resour
165、ces to help patients,their families,and their caregivers navigate their diagnosis and treatment journeys Supporting disease awareness and disease education through activities with patient advocacy groups,patient organizations,and professional medical associations Providing financial assistance to el
166、igible patients where necessary to help make sure those suitable to use our therapies have access to them Integrating patient perspectives,insights,and feedback from the beginning and throughout UTs clinical development programs Seeking to minimize insurance coverage barriers to enable access and se
167、tting pricing to reflect the benefit of our therapies to patients,society,and the overall health care systemWe call this Our Approach to Patient Engagement,visualized below:EducationPatientAdvocacyPatientsPatientSupportProgramMarket Accessand PricingPatient Engagement26MESSAGE FROM OUR CEO OUR PURPO
168、SEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESPediatric Cancer Education:Neuroblastoma is a very aggressive form of pediatric cancer,which is why nearly 70%of children who have it are diagnosed at an advanced stage of the disease.Our NEUROBLASTOMAinfo family-friendly website provid
169、es resources and tools to support families from diagnosis to treatment and beyond.These include videos,educational content about diagnosis and treatment options,links to advocacy groups,and award-winning resources for children who have questions about cancer.The PAH Initiatives mission is to improve
170、 the treatment and prognosis of adults living with PAH,help them navigate life,and move forward by providing both knowledge and inspiration.PAH Initiative resources are unbranded and do not reference specific UT therapies.Key programs include,but are not limited to the following:PAH Initiative Ambas
171、sadors Patients who inspire and share their own experiences with other patients through articles and videosPAH Today Magazine Our semi-annual magazine featuring real-life patients and caregivers who share their perspectives about finding their voice and advocating for their carePAH Today National Br
172、oadcast Series Series of interactive webinars every summer and fall featuring insights and perspectives on todays approaches to managing PAHSupport Group Resources Presentations to help educate patient support groups on PAH disease and other related topics of interest that they can further discuss w
173、ith their HCPs“Patient Voices”Meetings Meetings held several times annually to get timely feedback on our programs and materials;this feedback helps us understand patients experiencesThe PAH Initiative team also curates content featuring national broadcasts with experts,maintains social media pages
174、on Facebook,Instagram,and YouTube,and have translated materials into multiple languages to support other potentially underserved communities.27The Big Adventures of Little SkivoloEducationNon-medical factors that influence health outcomes are called social determinants of health(SDH),and one SDH fac
175、tor that can influence health equity and access is education.*Patient education and empowerment for key stakeholders are critical to providing effective management of rare and life-threatening diseases such as PH and neuroblastoma.We provide several no-cost educational solutions to help patients,the
176、ir caregivers,and families embark on their prescribed course of treatment together.Advancing Patient Care in PAH:We launched the PAH Initiative in 2019 to provide education and resources for adults affected by PAH.Almost 10,000 patients and caregivers,and on average more than 5,000 HCPs visit the we
177、bsite monthly and use the resources provided.*“Social determinants of health.”The World Health Organization.URL:https:/www.who.int/health-topics/social-determinants-of-health#tab=tab_1.Accessed June 2024.27MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXES
178、Patient Support Program We have dedicated teams who work hard to provide appropriate patient access to our treatments,supporting more than 32,000 patients on their treatment journey since 2010.PAH and PH therapies are specialty medications that bring with them unique complexities requiring in-depth
179、patient education to enable safe and effective administration.Our dedicated support teams provide education and resources to help patients,their HCPs and caregivers,and SPs and other customers,with information they need,ranging from securing patient access to UT therapies,to training on how to use o
180、ur therapies.This includes a co-pay assistance program through which eligible patients pay as little as$0 for needed therapies.UT patient assistance professionalLEARN MORE Our Patient Support ProgramsPatient Advocacy We engage with patient advocacy organizations,professional organizations,and founda
181、tions to better understand and help meet the needs of patients,caregivers,and others in the rare disease community.We provide financial support and educational grants to these organizations to help support their development and sustainment of resources for the patient and HCP community.For example,o
182、ver the past several years,we have supported or collaborated on materials with organizations such as the Pulmonary Hypertension Association(PHA);the Pulmonary Fibrosis Foundation(PFF);and the American Society of Transplantation(AST).28MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETO
183、UR PRACTICESREPORTING INDEXESMarket Access and Pricing In the U.S.,many independent and third-party health plans pay for patient use of our commercial products.Our Market Access Team works directly with government and commercial payers to try to obtain the best coverage for our therapies.We aim to c
184、onsider the benefits to patients,society,and the health care system in our pricing approach.This includes considerations of our long-term investments in medicine and organ manufacturing R&D,which are essential to make progress toward our PBC purpose.Our Health Economics and Outcomes Research Team re
185、gularly leads,collaborates on,and publishes studies that evaluate the value of our medicines by analyzing real-world outcomes such as hospitalizations,quality of life,treatment adherence,treatment satisfaction,and medical and pharmacy costs.This research includes an analysis of economic value,or how
186、 the medicine reduces the need for and overall costs associated with other health care interventions.We strive to comply with all applicable laws and regulations when establishing and communicating government and commercial prices.In addition,our policies are designed to adhere to U.S.state price tr
187、ansparency reporting laws and report prices as required.UT R&D team members at workLEARN MOREOur Patient Support ProgramsOur Corporate GivingOur Medical Education Grants and Scientific Sponsorships29MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESOur Peo
188、ple31 2023 Progress 32 Total Rewards33 Talent Acquisition and Development34 Diversity,Equity,and Inclusion35 Safe and Healthy Workplaces30MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXES2023 Progress We strive to hire exceptionally smart people who are p
189、assionate about our goals and who will thrive in our unique culture,which is why one of our objectives as a public benefit corporation is to Be a Destination Employer.Our Key Performance Indicators Voluntary turnover Diversity metrics and DEI initiatives Employee engagement as measured by third part
190、y and internal surveysProgress HighlightsVoluntary turnover:48%women 29%racially/ethnically diverse54%women 35%racially/ethnically diverse51%women 35%racially/ethnically diverse42%women 25%racially/ethnically diverse52%women 35%racially/ethnically diverseManagementNew HiresPromotionsBoard DiversityO
191、verall Workforce DiversityUN SDGs Alignment5%compared to a13.5%industry averageMore than 90%of employees responding to the Great Places to Work survey from 2018 through 2024 consider UT a Great Place to Work31MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDE
192、XESTotal RewardsSite net zero energy childcare center at our Silver Spring,Md.campus Our total rewards,benefits,and wellness programs are designed to attract,retain,and develop our workforce,which is why we continue to enhance our financial security,health,and wellness every year.Benefits include a
193、living wage,composed of cash compensation targets of at least$75,000 annually(base salary plus bonus target)for full-time Unitherians;an employee stock purchase plan;a 401(k)program with employee match;state of the art fitness centers and free cafeterias at certain key locations;access to medical,de
194、ntal,and vision benefits for eligible full-and part-time Unitherians;adoption and surrogacy assistance programs;parental bonding leave;paid time off for eligible full-and part-time employees;tuition reimbursement;a career framework;training plans and learning journeys;and much more.We recently enhan
195、ced benefits offerings in several areas,including providing access to medical,dental,and vision benefits to part-time employees;increasing our adoption assistance program for eligible full-and part-time employees;increasing travel benefits under our medical plan to enable access to medically necessa
196、ry procedures;and adding a pet wellness benefit.In 2024,we embraced a policy introduced to us by the Miromatrix team:employees are now eligible for paid leave to serve as a bone marrow donor or living organ donor.For detailed information about the benefits we provide our employees,see https:/ access
197、 to on-site daycare has been a unique benefit,as has the complimentary breakfast and lunch.Even better than the amenities though,I feel that I am fully able and encouraged to creatively solve problems.I am 100%fulfilled here;I love my job.”A Unitherian32MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOU
198、R PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESTalent Acquisition and DevelopmentOur culture is unique,so we make a point to be transparent about our purpose,approach to work,and growth objectives when engaging with prospective job candidates.In all our candidate interactions,we strive for open and
199、 honest communication,and we seek to regularly improve our recruitment efforts,including efforts to expand the diversity of our candidate pools to help us find the next generation of Unitherians wherever they may be.When a new Unitherian joins the team,we seek to prepare them for long-term success.W
200、e believe learning should be continuous,employee-driven,manager-supported,customized to the individual based on strengths and development needs,and blended using different modalities.We align with a 70/20/10 training model which holds that individuals gain 70%of their knowledge from on-the-job exper
201、iences,20%from interactions with others such as through mentoring,and 10%from formal educational events.We shape our training plans,learning journeys,and course offerings with input collected from people leaders,trends,and areas we have identified that require focus.We also customize courses to addr
202、ess specific team needs,covering topics such as team dynamics,communication,influencing without authority,and inclusion.For example,required training in 2023 included the following:100%completion of assigned environment,health,safety,and sustainability(EHSS),GMP,Code of Conduct training,and human re
203、sources curricular including assigned DEI training DEI training on allyship in action and bystander awareness Leadership training on building trust and accountability and leading powerful conversations required for all our people managers Management essentials course on UT policy and management resp
204、onsibilities for new managers Preventing harassment and discrimination,and training on diversity,inclusion,and belonging for new hiresUnitherians at our Melbourne,Fla.patient assistance office33MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESWe celebrate
205、 our diverse workforce and Board,and we firmly believe that being a great place to work means being a diverse,equitable,and inclusive place to work.We collaborate internally and externally to continue to advance our DEI ambitions.As employees of the biopharma industry,we have a special imperative to
206、 shoulder this work because the work of innovation to save lives requires cognitive diversity.We need creative minds who think differently to work together to find better solutions for our patients.That is part of why UT,like many other employers,supports employees in establishing employee resource
207、groups(ERGs).We believe that to achieve our public benefit purpose,we must recruit and retain smart,capable,creative people.We want to find those people wherever they are today,retain those who have joined us to solve the problems we face now,and nurture those future leaders who will build on these
208、efforts to create the solutions of tomorrow.ERGs can help us do that.Read an Impact Story about our ERG leaders and their work at UT here:https:/ InclusionAt UT,we are focused on fostering an inclusive culture through intentional practices that respect and value the diversity of individuals,while st
209、riving for equity and fairness in all aspects of our operations.Our ERGs have been an important part of our goal of fostering inclusion;they have given participating Unitherians a sense of belonging and a place to meet people who share common experiences.”Alyssa Friedrich Chief People Officer2024 Pr
210、ide celebration in Research Triangle Park,N.C.34MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESSource:NIOSH,https:/www.cdc.gov/niosh/hierarchy-of-controls/about/Hierarchy of ControlsMost effectiveLeasteffectiveEliminationSubstitutionEngineeringControlsA
211、dministrativeControlsPPEPhysically removethe hazardReplacethe hazardIsolate people from the hazardChange the way people workProtect the worker withPersonal Protective EquipmentSafe and Healthy WorkplacesAt United Therapeutics,we are dedicated to the well-being of our employees.We seek to be a global
212、 leader in protecting our people,partners,contractors,and communities in a safe and environmentally sustainable manner.In 2023,we implemented our incident reporting and investigation module integrated within our overall environmental,health,safety,and sustainability management system.Through the web
213、-based access of this module,employees can report hazards,near misses,and incidents with greater ease.The data trends provide aid in concentrating global initiatives to reduce hazards.Overview of our Safety Program The heart of our safety program is prevention.We encourage employees at all levels to
214、 contribute actively to our positive safety culture by promoting employee participation on our safety-focused committees and other collaborative initiatives.Our aim is to eliminate hazards and reduce safety risks where we work.We use the hierarchy of controls,developed by the National Institute for
215、Occupational Safety and Health(NIOSH),for controlling workplace hazards and protecting employees.Our integrated environmental and safety management system helps us control risks,manage centralized reporting,and oversee key aspects of safety and health.Focusing on leading safety indicators rather tha
216、n lagging safety indicators enables employees to take preventative action to address or eliminate a hazard in advance.Ongoing improvement is key for our safety program.Our leaders are expected to incorporate health and safety engineering practices into current processes and future projects.We are de
217、dicated to mitigating risks across all aspects of our global business operation,where we aim to foster a zero-incident culture while consistently meeting EHSS objectives and targets.35MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESTrain to EmpowerTo est
218、ablish a common baseline across functions,we provide regular safety training to employees,and in-depth role-based training where applicable.In line with our 70/20/10 training model at UT,we take an integrated approach to training,using multiple methods including on-the-job trainings,shorter micro-le
219、arnings,and online modules.An important objective of our safety program is to help people identify risks and empower employees to speak up.We support several voluntary,employee-owned safety committees established to facilitate safety conversations across departments and across locations.These safety
220、 committees seek to empower everyone at UT to create and maintain a safe and healthy workplace by reducing risk and preventing injuries.Identify and EliminateInternal and external auditors routinely audit our health and safety programs and performance.We regularly assess health-related risks to empl
221、oyees,contractors,and visitors,and seek to proactively manage those risks across our operations.For example,we complete periodic industrial hygiene monitoring studies across our business units.This data is tracked utilizing our industrial hygiene module within our overall environmental,health,safety
222、,and sustainability management system,allowing us to monitor industrial hygiene for our employees and our environment.Unitherians engaging in on-the-job training in a UT laboratory36MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESImproveWe prioritize spo
223、tlighting and amplifying leading practices that become part of our safety culture.For example,in 2023 we improved employee accessibility to our Safety Data Sheet(SDS)library by integrating an online SDS module available to all employees.By using this online system,employees have 24/7 year-round acce
224、ss to the industrys leading safety data sheet database.The EHSS team partners with our Enterprise Risk Management(ERM)team to review the flammable storage and handling programs,and collaborates with our Corporate Real Estate(CRE)team and our design and build project consultants to integrate environm
225、ental,health,safety,and sustainability requirements and features into facility design.LEARN MOREOur Culture and People OverviewOur Historical Awards and RecognitionsOur Benefits and AmenitiesOur Corporate Code of ConductThe building management systems at our DPF facility support the health and safet
226、y of all its occupants37MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESOur Planet39 2023 Progress40 Environmental Stewardship38MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXES*Square footage calculation does
227、 not include properties acquired with Miromatrix and IVIVA acquisitions.Secured LEED Gold Certification at our Phase Five,cold storage cGMP warehouse in Research Triangle Park,N.C.Maintained our sustainable facility portfolio,including our LEED Platinum site net zero energy commercial building calle
228、d the Unisphere and two LEED Gold Certified facilities in Silver Spring,Md.;with Phase Five,our LEED certified properties represent approximately 26%of our portfolio by square feet*Added incrementally to our almost 7-MW onsite solar capacity EV Chargers:Added units to our more than 55 free-to-use el
229、ectric vehicle(EV)charging stations across our footprint for employees and visitors Composting and Waste Diversion:Expanded composting programs for cafeteria wastes at our two headquarters locations where more than 70%of our employees work,and composted more than 72,000 pounds of organic waste acros
230、s both campusesMade progress toward assurable Scope 1 and 2 GHG emissionsUN SDGs Alignment2023 ProgressWe believe acting sustainably and being aware of our environmental impacts are crucial to achieving our purpose and humankind goals.Our Key Performance Indicators New construction site net zero ene
231、rgy where possible Environmental data trends Progress toward assurable Scope 1 and 2 GHG emissions inventoriesProgress Highlights39MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESEnvironmental StewardshipEnvironmental Health,Safety,and Sustainability Pol
232、icy Statement At United Therapeutics,we acknowledge the interconnectedness of life,including human well-being and the environment.We are fully committed to complying with all applicable local,state,and federal environmental,health,and safety obligations.Our commitment to social responsibility and en
233、vironmental responsibility is encoded in our public benefit purpose and compels us to advance life saving therapies in a responsible way that protects our employees,patients,customers,suppliers,neighbors and the environment.This EHSS Policy applies to all employees and contractors at United Therapeu
234、tics locations.Health and Safety.We are dedicated to the well-being of our employees.Our aim is to eliminate hazards and reduce safety risks where we work.Employees are required to complete annual refresher health and safety training,and we provide employee access to our health and safety policies,p
235、rocedures,and programs through an integrated environmental health,safety,and environmental sustainability management system.Environmental Responsibility.We prioritize pollution preventionon land,in water,and in airand strive to use energy and natural resources efficiently.This involves use of renewa
236、ble energy wherever feasible,At United Therapeutics,we adopted the mindset that we could develop life-saving medicines for patients without harming the planet.”composting,recycling,repurposing,responsibly disposing of hazardous and non-hazardous wastes,minimizing water use,and returning water to the
237、 environment of equal or improved quality than we received it.Climate.We monitor and manage our greenhouse gas(GHG)emissions,implement strategies that bolster climate resilience through the innovative design of our facilities,including the expansion of our Site-Net Zero Energy and LEED Certified bui
238、lding portfolio.Continuous Improvement.We strive to improve our EHSS programs and performance by reporting our progress,both internally and externally.We are dedicated to mitigating risks across all aspects of our global business operations,where we aim to foster a zero-incident culture while consis
239、tently meeting EHSS objectives and targets.We are committed to developing the highest-quality therapies that improve the life of our patients while valuing the well-being of our people and communities.Through innovative collaboration and shared commitment to our people and environment,we can create
240、a healthier and more sustainable world for future generations.EHSS 520.01 Revision 1Dr.Martine Rothblatt Chairperson and CEO40MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESSustainable FacilitiesWe recognize the links between environmental impacts and h
241、uman healthparticularly those related to air quality and climate change.That is why we have had a long-established commitment to addressing the environmental footprint of our built environment through the construction of site net zero energy facilities where feasible.This ambition has also inspired
242、our corporate real estate team to work with collaborators on the most innovative and groundbreaking facilities yet seen.The experiences generate lessons we apply to the new construction projects that follow.Starting in 2003 with the installation of our first solar array,we now have more than 7MW cap
243、acity of onsite solar powering our operations,with about 26%of our portfolio by square foot certified to LEED Gold or better,including our LEED Platinum certified site net zero energy commercial office building we call the Unisphere.Quick Facts*Annual home consumption source:U.S.Energy Information A
244、dministration(eia.gov)Average fueling cost source:https:/www.nrdc.org/stories/electric-vehicle-charging-explainedInside our Research Triangle Park,N.C.campus 7,000 MWh(generated from 7MW capacity)is the amount of power needed for almost 3,000 typical single-family homes in the U.S.annually*More than
245、 one in every four square feet in our facility footprint is LEED Certified Gold or betterOur EV charging stations help Unitherians save on fueling costs compared to conventional gasoline powered vehicles41MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESP
246、hase Five warehouse(Project Lightyear when in development)on our Research Triangle Park,N.C.campusProject Lightyear(Phase Five)was awarded LEED Gold certification in 2023.To put this in context,as of June 12,2024,there were just over 1,000 LEED certified warehouse and distribution center facilities
247、globally listed on the LEED public registry of projects.Of these,about 10%have achieved LEED Gold;to our knowledge,there are few if any other cGMP-compliant facilities on the list.This facility received honorable mention recognition under the 2024 International Society for Pharmaceutical Engineering
248、(ISPE)Facility of the Year Award(FOYA)Program.Typically,ISPE FOYA winners are manufacturing or research labs.The FOYA judging team made an exception for our Phase Five warehouse,recognizing it for its design toward site net zero energy and net zero carbon innovations.*The team integrates lessons lea
249、rned from one project to the next.The CRE team is already incorporating lessons learned from the construction of Phase Five to one of the next big projects on the horizon called Warp10,which we are currently designing to use similar technologies in combination with another first-of-its-kind endeavor
250、:a mass timber*cGMP pharmaceutical manufacturing facility.United Therapeutics was honored to receive the 2023 American Society of Civil Engineers National Capital Section(ASCE-NCS)Innovation in Sustainable Engineering Award for the Unisphere,our flagship LEED Platinum site net zero energy certified
251、commercial office building in Silver Spring,Md.Awards are made annually to a civil engineering project in recognition of creativity in the form of innovative sustainability.Avi Halpert,VP Government Affairs and Community Relations,third from left,pictured with,from left to right,Alex Rosenheim,Susta
252、inability Chair ASCE-NCS,Jared Mechling,Sr.Project Manager at The Whiting-Turner Contracting Co.,and Elizabeth Wheeler,President,ASCE-NCS*2024 ISPE FYOA Category Winner-Honorable Mention.ISPE.https:/ispe.org/facility-year-awards/winners/2024/honorable-mention*Mass timber construction uses wood inste
253、ad of steel or concrete in the construction of commercial buildings.According to the Mass Timber Institute at the University of Toronto,estimates indicate that one cubic meter of mass timber sequesters one metric ton of CO2,while every ton of manufactured cement produces about half a ton of CO2.See
254、https:/academic.daniels.utoronto.ca/masstimberinstitute/for more information.LEARN MOREOur Sustainable Facilities Overview42MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESOur Approach to ClimateWe believe in the imperative to measure and manage our clim
255、ate-related impacts.We have integrated our Scope 1 and Scope 2 data into our centralized software system in alignment with the Greenhouse Gas Protocol Corporate Accounting and Reporting Standard(GHG Protocol),and we are completing work in 2024 to better align with the Task Force on Climate Related F
256、inancial Disclosures(TCFD).We have been readying our Scope 1 and Scope 2 emissions for disclosure,and our current calculations of location-based emission lead us to believe our emissions are significantly lower than those reported about us by third-party ESG rating agencies,which are modeled using a
257、verage industry information.As eager as we are to share these results with our stakeholders,we want to be confident in the accuracy and reliability of our calculations.With the support of a third-party vendor,we undertook an assurance readiness audit in 2024 and are working with our environmental co
258、nsultants to close gaps in our program and data.We are also mindful of evolving regulatory standards,and want to make sure that any GHG reporting is compliant with any laws and regulations to which we are subject(e.g.,SEC and California requirements),and that we reduce the likelihood of having to re
259、state previously-published data once those regulations go into effect.We are working with external experts to help us prepare for future disclosures,including helping us make affirmative decisions related to the use of marketplace tools like carbon offsets or even renewable energy credits(RECs),some
260、 of which have come under scrutiny related to their promised beneficial impacts.In 2025,we plan to disclose how we are examining and preparing for climate risks in alignment with TCFD guidance.We remain steadfast in creating a robust,data-driven,and comprehensive plan and set of policies to mitigate
261、 our carbon footprint and better understand climate risks to our business.To do this in accordance with best industry practices,we are aware that this is a long journey comprised of several steps.While we are starting with Scope 1 and Scope 2 emissions,we have begun work to evaluate our total climat
262、e impact,including Scope 3 emissions.We intend to report on our progress in future reports.Ecosystem Impact ManagementWe believe the health of the ecosystems we live in are important to achieve our mission.Our environmental policies align with ISO 14001 and other applicable environmental laws and re
263、gulations.We seek to prioritize pollution prevention in our operations.Our aim is to safeguard natural resources,including clean air and water.Clean AirAt United Therapeutics,we have a special connection to breathing.We strive to do our part to help keep the air in the communities where we operate a
264、s clean and healthy as possible.For our new facilities,we prioritize the installation of cleaner-burning natural gas engines instead of diesel where feasible.Water StewardshipWe partner with our water and wastewater authorities.Our manufacturing facilities are designed to utilize water responsibly a
265、nd operate within regulatory requirements.We have an outstanding track record in meeting wastewater discharge standards while we continue to improve water management practices.We have consistently earned water stewardship awards at our Silver Spring,Md.,campus over the last several years.For example
266、,again this year,we received the Washington Suburban Sanitary Commission Gold Level award for the 2023 calendar year for five or more consecutive years of consistent compliance.Responsible Waste ManagementWaste management is a key aspect of our sustainability efforts.We seek to manage and minimize w
267、aste.We collaborate with our waste management providers and our facilities and operations teams to manage regulated waste using compliant container storage and labelling,careful packaging,maintaining accurate waste profiles,and shipping to audited storage and treatment facilities.We strive to practi
268、ce waste minimization through container reuse,landfill free disposal where feasible,and waste-to-energy treatment where appropriate to the material.43MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESOther Sustainability InitiativesBeyond our decarbonizati
269、on efforts,internal environmental management,and regulatory alignment,we continue to look for other avenues to adopt sustainable practice,program,and policies.For example,we continue to progress the efforts listed in our 2023 Corporate Responsibility and Public Benefit Report.These include:Our Green
270、 Chemistry efforts Our composting programs at our two headquarter locations,where we diverted from landfill more than 72,000 pounds of food waste in 2023equivalent to just over six average-sized African elephantsand allowing for the generation of a useful byproduct from food waste and compostable fo
271、odservice containers Membership in the Pharmaceutical Product Stewardship Work Group(PPSWG)MyOldMeds program to facilitate proper disposal of unwanted,unused,or expired household medicines 55+dual EV charging stations across our sites,free to use for employees;thats basically one EV charger for ever
272、y 11 employees SmartBenefits for employees in the DC-metro area to help commuters take advantage of lower carbon local public transitDriven by insights from patient experiences and feedback from our warehouse team and SP partners,the work inspired a new commitment to integrate environmental principl
273、es to the extent feasible into new product packaging.Read more about this Impact Story here:https:/ Less is More:How Packaging Redesign Serves Our Patients and the Planet.We concluded a packaging redesign project in 2024 for one of our products that is expected to result in the following:uses up to
274、65%less plasticreduce material costs by up to 70%use up to 73%less packaging material compared to the previous formatsdecrease the estimated GHG over the previous packaging format by up to almost 80%Todd Tuescher,Senior Director of Medical Device Operations,and Katie McMahon,Associate Manager of Med
275、ical Device Operations,stand with before and after versions of our Tyvaso packaging44MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESOur Practices46 Governance48 Ethics and Compliance49 Grants and Giving51 Data Privacy and Security 52 Enterprise Risk Man
276、agement and Organizational Resilience 45MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESGovernanceWe believe our strong corporate governance practices have helped us maintain our focus on our public benefit purpose.Our Board operates through a culture of
277、 independent thought and intelligent conversation on critical topics.We have taken a year-round view of corporate governance and adopted leading practices in several areas,and have a robust semi-annual shareholder outreach practice led by two of our independent directors.We are pleased to have added
278、 Jan Malcom to the Board of Directors upon election by shareholders at our June 2024 annual meeting.Ms.Malcom was the Minnesota Commissioner of Health under three governors,and during her tenure she earned a national reputation as one of the first health care leaders to highlight health disparities
279、and the impact of social determinants of health.She has both operational healthcare and leadership experience,which complements and supplements the skills of other Board members.ESG and PBC GovernanceWe have an active,engaged,and diverse Board of Directors,which oversees our key business strategies
280、and objectives,our risk management process,and our compliance program.Our Boards Nominating and Governance Committee has formal oversight of our ESG program and PBC goal setting,performance assessment,and reporting.The following illustrates our ESG governance model.Members at all levels of this gove
281、rnance model were provided an opportunity to review and modify the content of this Report before publication.NOMINATING AND GOVERNANCE COMMITTEEEXECUTIVE LEADERSHIP TEAMESG CABINETStrategic Oversight Provides advisory oversight and governance of our PBC purpose and ESG program Receives updates at la
282、st semi-annually on our ESG and PBC activities;the entire Board is briefed on these activities at least annually Contracts with external consultants to enhance the Committees ESG knowledge,including on climate-related issuesExecutive Direction and Support Led by our CFO,provides executive sponsorshi
283、p of ESG program and disclosure decisions Reviews and advises on the program,strategy,and priorities Meets as neededStewardship and Action Chaired by our ESG and PBC Transparency Director,establishes and oversees execution of ESG program,strategy,tactics,and disclosure,including climate-related ambi
284、tions Represents key functions across the organization,including EHSS,Corporate Real Estate,Human Resources,Finance,Investor Relations,Accounting,Manufacturing,Quality,Legal,Innovation,Enterprise Risk Management,Procurement,and others as needed Leads and oversees expert action teams charged with imp
285、lementing ESG priorities Typically meets every other month46MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESBoard Risk OversightWe take risk oversight very seriously.Our Board Committees are each charged with various risks,providing oversight to our mana
286、gement team and their efforts to identify and mitigate the risks most relevant to our company.Board CommitteeKey Risk Oversight AreaNominating and Governance CommitteeEnterprise risk management system;corporate compliance program;and PBC/ESG activities,including climate-related risksAudit Committee
287、Auditing,accounting,and financial matters,as well as cybersecurityCompensation CommitteeCompensation programs,as well as DEI and other human capital prioritiesUseful ResourcesFor additional details about our Board and our corporate governance and business practices,please visit these resources:Confl
288、ict Minerals Disclosure May 31,2024 United Therapeutics Corporation(UT)believes in the importance of social responsibility in the supply chain of its materials,including considerations and requirements for environmental,safety,health,and human rights.This includes efforts to comply with rules and re
289、gulations promulgated by the U.S.Securities and Exchange Commission to implement Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act(the Conflict Mineral Rules).These rules require UT to conduct,in good faith,a reasonable country of origin inquiry that is reasonably designe
290、d to determine whether Conflict Minerals(defined below)necessary to the functionality or production of products manufactured or contracted to be manufactured by UT originated in Covered Countries(defined below)or came from recycled or scrap sources.The Conflict Mineral Rules define Conflict Minerals
291、 as cassiterite,columbite-tantalite,gold,wolframite,and their derivatives(which are limited to tantalum,tin,and tungsten).Covered Countries is defined as the Democratic Republic of the Congo and its adjoining countries.In accordance with the Conflict Mineral Rules,UT has determined that it has two p
292、roducts that contain Conflict Minerals(the Relevant Products).UT has conducted a good faith,reasonable country of origin inquiry(as described below)and determined that UT has no reason to believe that the Conflict Minerals in the Relevant Products may have originated in the Covered Countries.Therefo
293、re,UT is not required to provide a conflict minerals report with respect to the Relevant Products.UT contracts to manufacture the Relevant Products,and does not directly purchase Conflict Minerals included in the products.UTs reasonable country of origin inquiry included an examination of the bill o
294、f materials and approved supplier list for the Relevant Products.Based on that review,UT conducted a comprehensive inquiry of a total of 110 companies,representing all of UTs direct suppliers relating to the Relevant Products and their respective first and second-tier component suppliers.UT requeste
295、d each supplier provide a written statement regarding its use of Conflict Minerals to determine whether any Conflict Minerals originating in Covered Countries(and not from scrap or recycled sources)were incorporated into the Relevant Products.UT received responses from all of these suppliers,and,bas
296、ed on their responses,had no reason to believe Conflict Minerals necessary to the functionality or production of the Relevant Products either:(1)originated from Covered Countries;or(2)were sourced from a smelter that the Responsible Business Alliance had determined to be non-compliant with its Respo
297、nsible Minerals Initiative assessment protocols.This Conflict Minerals Disclosure is publicly available on UTs website,located at:http:/ This document has been approved by the Board of United Therapeutics Europe Limited(UTEL)and sets out the Groups(defined as UTEL and all of its affiliated entities)
298、approach to handling its UK tax affairs and managing its UK tax risks,for the period ended 31 December 2023.For the avoidance of doubt,UTEL is the only UK entity within the Group that is subject to UK taxation.This document is intended comply with the Groups requirements under Schedule 19 of the Fin
299、ance Act 2016.Risk management and governance United Therapeutics Corporation(UTC),as the ultimate parent of UTEL,bears responsibility for ensuring compliance with UK tax law and regulations.In addition,UTC is responsible for ensuring that UK tax risk is managed in accordance with the Groups attitude
300、 to towards acceptable levels of tax risk.To assist with the tax risk management,the Group has in place processes to identify and manage areas where material tax risks could arise.These processes include seeking external advice to ensure compliance with the tax legislation and regulations,in order t
301、o reduce the tax risk to an acceptable level.These processes are reviewed on an annual basis to ensure that material tax areas continue to be covered.Tax planning The Group is committed to paying the amounts of tax legally due in the UK,whilst ensuring tax efficiency in accordance with the commercia
302、l objectives of the business.Tax planning may therefore be undertaken to utilise tax incentives or opportunities,where these align with business operations,and meet the intended objectives of the legislation.For the avoidance of doubt,the Group does not seek to reduce UK tax by entering into artific
303、ial transactions which lack economic substance.In the majority of instances where tax planning is undertaken,the Group seeks external advice to ensure that the planning is carried out in a tax efficient manner,but also that the planning is carried out in accordance with the spirit of the legislation
304、 which does not give a result contrary to the intentions of parliament.Acceptable levels of risk The Group has a conservative approach to acceptable levels of UK tax risk and typically,only a minimal(non-material)level of tax risk will be accepted.The Groups approach is that each material transactio
305、n is reviewed on a case by case basis prior to accepting any risk.Where there is uncertainty with regards to the intention of the legislation,or how it should be applied,external advice may be sought to help assess the risk and assist in the Groups decision-making process.The Group is committed to e
306、nsuring that decisions regarding acceptable levels of tax risk are made at the appropriate level,and that the individuals involved apply diligent professional care and judgement to arrive at well-reasoned conclusions as to whether the risk should be accepted or how it should be managed.UK TAX STRATE
307、GY Proxy StatementAnnual ReportConflict Minerals DisclosureUK Tax StrategyCorporate Governance website47MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESEthics and ComplianceWe prioritize acting with integrity and the highest ethical standards in everythi
308、ng we endeavor to do.The United Therapeutics Compliance Program provides structure,governance,and resources to help embed that our ethical policies and behavior across our operations and business relationships.Our Compliance Principles revolve around the overarching tenet that WE DO THE RIGHT THING.
309、Other principles include:We are passionate for patients We respect privacy We dont pay to play We communicate ethically and honestlyAt United Therapeutics,we are inspired and guided by our values.Our Compliance Principles provide the foundation of integrity while our Code of Conduct and compliance p
310、olicies provide the tools that help all Unitherians DO THE RIGHT THING.”Rebecca McCarty Sr.VP,Chief Compliance OfficerSpeak up!Unitherians are encouraged to contact their manager or the Compliance Team to address any compliance-related questions or to raise compliance concerns.Employees may also fil
311、e a report using EthicsPoint,a comprehensive end confidential reporting tool that maintains a 24/7/365 anonymous phone line.LEARN MORE Our Ethics and Compliance Program OverviewOur Animal Welfare PolicyOur Code of Conduct48MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICES
312、REPORTING INDEXESGrants and GivingAs part of our promise to our patients,we fund innovative,high impact research projects that relate to our therapeutic areas of focus as well as organ transplantation.We also recognize the importance of,and are committed to,providing funding for initiatives offered
313、by medical societies,hospitals,and patient organizations,including those organizations that host conferences,health and wellness fairs,and patient educational events.We remain intent on being a good neighbor and a good corporate citizen;we provide funding,in-kind donations,and direct service opportu
314、nities for employees with organizations that benefit local communities,support youth,advance science,technology,engineering,and math(STEM)education,and contribute broadly toward the advancement of a brighter future for everyone as reflected in the promise of the UN SDGs.In 2023,we provided approxima
315、tely$5.6 million in grants,sponsorships,and financial donations to about 140 organizations.This includes the$100,000 each we provided to the three awardees of our flagship Jenesis Awards ProgramTM in 2023.14%Charitable Grants-Local and Global9%Diversity,Equity,and Inclusion19%Medical Education Grant
316、s29%Patient Advocacy5%ResearchGrants20%Sponsorships4%STEM Educationand YouthDevelopmentWe also provided in-kind donations at a value of almost$1 million to several local colleges and universities and other local organizations.In 2023,we continued to sponsor volunteer days enabling and encouraging em
317、ployees to spend time during the workweek to support local community groups.Over the past several years,we have sponsored almost 40 volunteer days and facilitated thousands of employee volunteer days with organizations local to our sites of operation.49MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR
318、 PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESExample:Holt Brothers Foundation The Holt Brothers Foundation raises money to support kids who have a parent or guardian with cancer.The entity was founded by North Carolina State University graduates and former NFL players,Terrence and Torry Holt,who w
319、ere inspired by their mothers cancer diagnosis when they were children.2023 was United Therapeutics first year participating as a corporate sponsor for the Holt Brothers Foundations main fundraising event,The Holt Brothers Tournament.Unitherians took to the field for the flag football and cornhole t
320、ournaments and enjoyed fellowship with each other at the United Therapeutics tailgate.Unitherians pictured in 2024 with brothers,former NFL players,and North Carolina State University graduates,Terrence and Torry Holt at The Holt Brothers Tournament to raise money to support children whose parent or
321、 guardian has cancer.Photo credit:Jared Burn MediaLEARN MORE Our Grants and Giving OverviewThe Jenesis Awards ProgramOur Corporate Giving RequirementsOur Medical Education Grants and Scientific Sponsorships Requirements50MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESRE
322、PORTING INDEXESData Privacy and Security One of our core values is“We respect privacy.”Gathering and using certain personal information from various sources,including patients,clinical trial subjects,customers,HCPs,and our employees,is core to our business.We are committed to protecting the privacy
323、of this information.We do this through robust data privacy and cybersecurity programs and by driving training and awareness for our Unitherians.DEDICATED DATA PRIVACY EMAILOur employees,patients,and other third parties can reach us for any data privacy requests or questions at .Cybersecurity Governa
324、nce and ProcessWe use a“defense in depth”cyber strategy that is designed to leverage multiple layers to protect our information and build operational resiliency.We also emphasize innovation so that our information systems enable continued patient-focused R&D innovation.We have established a robust c
325、ybersecurity governance structure that is intended to operate under a comprehensive and strict set of standards.LEARN MORE Our Data Privacy and Security OverviewOur Privacy PolicyBOARD AUDIT COMMITTEEEXECUTIVE LEADERSHIPCYBERSECURITY MANAGEMENTOversightThe Director of Information Security,Risk,and C
326、ompliance provides written reports to the Chair of the Audit Committee each quarter,leads a discussion with the full Audit Committee and independent auditor annually.Strategy DevelopmentThe Director of Information Security,Risk,and Compliance reports directly to the Chief Information Officer,who in
327、turn reports to our Chief Operating Officer.We have a highly-engaged executive leadership team that understands and is aligned on our cybersecurity approach.Strategy Execution and Operational ManagementThe Information Security Team leverages the National Institutes of Standards and Technology Cybers
328、ecurity Framework.The Data Privacy Office and Information Technology operations teams,led by the Director of Information Security,Risk,and Compliance,collaborate on implementing proper controls for data protection and data use.Information Technology security team members have industry-leading securi
329、ty certifications such as Certified Information Systems Security Professional,Certified in Risk and Information Systems Control,and Certified Information Privacy Manager.51MESSAGE FROM OUR CEO OUR PURPOSEOUR PATIENTSOUR PEOPLEOUR PLANETOUR PRACTICESREPORTING INDEXESEnterprise Risk Management and Org
330、anizational Resilience The Enterprise Risk Management Program is an important aspect of our corporate strategy,and we use a variety of methods in our efforts to help us appropriately manage our enterprise risks.The Organizational Resilience Program is a central component of our risk management strat
331、egy designed to assess,mitigate,and respond to key operational risks throughout the enterprise.Our ERM Governance and OperationsEffective ERM starts with clarity around risk strategy and governance,with the following roles and responsibilities of key stakeholders:BOARD NOMINATING AND GOVERNANCE COMM
332、ITTEEEXECUTIVE SPONSORSENTERPRISE RISK PROGRAM MANAGEMENTOversightThe VP of Risk Management provides periodic and annual reports to the Nominating and Governance Committee and to the full Board of Directors.In its oversight role,the Committee:Maintains awareness of the enterprise risks facing United
333、 Therapeutics and provides guidance Oversees enterprise risk management activitiesStrategy AlignmentThe VP of Risk Management consults with executive sponsors to confirm strategic alignment on corporate objectives and business needs.Executive sponsors:Include our CEO,President and COO,CFO,General Counsel,and EVP,Technical Operations Maintain alignment between the ERM assessment and corporate objec
0731-84720580
sgpjbg002
工作日 9:30 - 18:00
研報
新質生產力
DeepSeek?
低空經濟
大模型
AI Agent
AI Infra
具身智能
自動駕駛
寵物
銀發經濟
人形機器人
企業出海
算力
微短劇
薪酬
白皮書
創新藥
人工智能
AI產業
信息科技
互聯網
消費經濟
汽車交通
電商零售
傳媒娛樂
醫藥健康
投資金融
能源環境
地產建筑
傳統產業
英文報告
其它
最新報告
中英對照
全文搜索
報告精選
PDF上傳翻譯
多格式文檔互轉
入駐&報告售賣
會員權益
機構報告
券商研報
財報庫
專題合集
英文報告
數據圖表
會議報告
其他資源
行業聚焦
芯片產業
熱點概念
全球咨詢智庫
人工智能
500強
新質生產力
會議峰會
新能源汽車
企業年報
互聯網
公司研究
行業綜觀
消費教育
科技通信
醫藥健康
人力資源
投資金融
汽車產業
物流地產
電子商務
傳統產業
傳媒營銷
其它
2025低空經濟/低空產業報告合集（共49套打包）
2025年智算中心/AIDC/AI數據中心研究報告合集（共37套打包）
AI、科技與通信
廣告、傳媒與營銷
消費、零售與支付
HR、文化與旅游
金融、保險與投資
能源、環境與工業
醫療制藥與大健康
物流、地產與建筑
其他行業
AI ? 科技 ? 通信
數字化
金融財經
智能制造
電商傳媒
地產建筑
醫療醫學
能源化工
其他行業
收藏
下載
2025-05-20
AI查數
行業數據
政策法規
商業模式
產業鏈
競爭格局
市場規模
產業概述
其它
2025年
AI讀財報
年報
一季報
半年報
三季報
IPO招股書
社會責任報告
A股
IPO申報
港股
美股&全球
新三板
掃碼登錄
手機快捷登錄
賬號登錄
